EBMT 2022 | Quadruplet therapy with and without autoHSCT in NDMM
Meral Beksac, MD, Ankara University, Ankara, Turkey, discusses the efficacy of quadruplet therapy with or without stem cell transplantation (SCT) in newly diagnosed multiple myeloma (NDMM). The MANHATTAN study has shown that patients treated with quadruplet therapy only are able to achieve similar outcomes to patients treated with quadruplet therapy followed by SCT. However, it is still necessary to determine the optimal number of induction cycles, as well as the best induction strategy. According to Dr Beksac, quadruplet therapy may be used to achieve measurable residual disease (MRD) negativity prior to transplant, and triplet induction therapy followed by SCT is likely to remain the main treatment strategy for NDMM in countries where quadruplet regimens have not yet been approved. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
